With regard to the role of Zeb1 and Zeb2 in AML progression, we have demonstrated that KO of Zeb2 can significantly extend survival in MLL-AF9 AML transplant settings in vivo. The gene discussed is KMT2A; the disease is acute myeloid leukemia.